HomeMarketsDiscoverWatchlistPortfoliosScreener
Sign Up or Login
  • Sweden

Swedish Biotech Stock News

OM:BIOA B
OM:BIOA BBiotechs

BioArctic AB (publ)'s (STO:BIOA B) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

September 28, 2023
BioArctic (STO:BIOA B) has had a rough month with its share price down 14%. But if you pay close attention, you might...
OM:PROB
OM:PROBBiotechs

Probi AB (publ) (STO:PROB) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

September 25, 2023
Probi's (STO:PROB) stock is up by a considerable 13% over the past three months. But the company's key financial...
OM:SOBI
OM:SOBIBiotechs

Swedish Orphan Biovitrum AB (publ) (STO:SOBI) is a favorite amongst institutional investors who own 38%

September 23, 2023
Key Insights Institutions' substantial holdings in Swedish Orphan Biovitrum implies that they have significant...
OM:HNSA
OM:HNSABiotechs

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

September 22, 2023
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
OM:DMYD B
OM:DMYD BBiotechs

We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully

September 22, 2023
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
OM:VICO
OM:VICOBiotechs

We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully

September 21, 2023
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
OM:VITR
OM:VITRBiotechs

Should Weakness in Vitrolife AB (publ)'s (STO:VITR) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

September 20, 2023
Vitrolife (STO:VITR) has had a rough three months with its share price down 34%. However, the company's fundamentals...
OM:GUARD
OM:GUARDBiotechs

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

September 20, 2023
We can readily understand why investors are attracted to unprofitable companies. For example, although...
OM:IMMU
OM:IMMUBiotechs

Market Sentiment Around Loss-Making Mendus AB (publ) (STO:IMMU)

September 14, 2023
Mendus AB (publ) ( STO:IMMU ) is possibly approaching a major achievement in its business, so we would like to shine...
OM:BIOG B
OM:BIOG BBiotechs

Calculating The Intrinsic Value Of BioGaia AB (publ) (STO:BIOG B)

September 13, 2023
Key Insights The projected fair value for BioGaia is kr95.22 based on 2 Stage Free Cash Flow to Equity BioGaia's...
OM:XSPRAY
OM:XSPRAYBiotechs

Xspray Pharma's Recent Gains Improve Losses On Insider Purchases Worth kr6.5m

September 12, 2023
Insiders who bought kr6.5m worth of Xspray Pharma AB (publ) ( STO:XSPRAY ) stock in the last year recovered part of...
OM:BIOVIC B
OM:BIOVIC BBiotechs

Biovica International AB (publ) (STO:BIOVIC B): Are Analysts Optimistic?

September 09, 2023
Biovica International AB (publ) ( STO:BIOVIC B ) is possibly approaching a major achievement in its business, so we...
OM:EGTX
OM:EGTXBiotechs

Insider Buyers Lose kr254k As Egetis Therapeutics Sheds kr125m

September 06, 2023
The recent 11% drop in Egetis Therapeutics AB (publ)'s ( STO:EGTX ) stock could come as a blow to insiders who...
OM:BINV
OM:BINVBiotechs

Bernd Seizinger Bought 120% More Shares In BioInvent International

September 05, 2023
Even if it's not a huge purchase, we think it was good to see that Bernd Seizinger, the Independent Director of...
OM:DVYSR
OM:DVYSRBiotechs

Independent Director of Devyser Diagnostics Fredrik Dahl Buys 78% More Shares

September 03, 2023
Even if it's not a huge purchase, we think it was good to see that Fredrik Dahl, the Independent Director of Devyser...
NGM:APTA
NGM:APTABiotechs

Aptahem Reports Second Quarter 2023 Earnings

September 03, 2023
Aptahem ( NGM:APTA ) Second Quarter 2023 Results Key Financial Results Net loss: kr2.74m (loss widened by 53% from 2Q...
OM:CYXO
OM:CYXOBiotechs

When Will Cyxone AB (publ) (STO:CYXO) Become Profitable?

September 02, 2023
We feel now is a pretty good time to analyse Cyxone AB (publ)'s ( STO:CYXO ) business as it appears the company may be...
OM:CRNO B
OM:CRNO BBiotechs

Will Cereno Scientific (STO:CRNO B) Spend Its Cash Wisely?

September 01, 2023
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
OM:BINV
OM:BINVBiotechs

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

September 01, 2023
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
OM:DVYSR
OM:DVYSRBiotechs

These Analysts Just Made An Incredible Downgrade To Their Devyser Diagnostics AB (publ) (STO:DVYSR) EPS Forecasts

August 30, 2023
Today is shaping up negative for Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders, with the analysts delivering...
OM:VITR
OM:VITRBiotechs

An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued

August 25, 2023
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vitrolife fair value estimate is kr202 Current share price of...
OM:ABLI
OM:ABLIBiotechs

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

August 24, 2023
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
OM:CANTA
OM:CANTABiotechs

Analysts Expect Breakeven For Cantargia AB (publ) (STO:CANTA) Before Long

August 20, 2023
With the business potentially at an important milestone, we thought we'd take a closer look at Cantargia AB (publ)'s...
OM:SOBI
OM:SOBIBiotechs

Possible Bearish Signals With Swedish Orphan Biovitrum Insiders Disposing Stock

August 19, 2023
Over the past year, many Swedish Orphan Biovitrum AB (publ) ( STO:SOBI ) insiders sold a significant stake in the...
  • 1
  • 2
  • 3
  • 4
  • 5
Next

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.

Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
  • About
  • Careers
  • Plans
  • Log In
  • Help Centre
  • Latest Coverage
  • Podcasts
  • Financial Services Guide
  • Terms and Conditions
  • Privacy Policy

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.